During the Study:

• Subject is required to visit every week for the first 2 months and then every month till completion of study or as and when required
• The usual symptomatic and supportive treatment of Chronic Liver Disease, including use of antiviral, will be given to all patients.
• Effort will be made to avoid use of other hepatotoxic drug(s) during Anti-Tubercular Treatment.
• Liver function tests (LFT) will be done weekly during first 2 months then at one month interval or as when required.
• The treatment efficacy of Anti-Tubercular Treatment (ATT) will be made on the basis of clinical, biochemical, microbiological and imaging parameters at months 2, 4, 7 and 9. Patients not improving at 4 weeks after initiation of treatment will be shifted to alternative regimens and will be excluded from the study.

Inclusion Criteria:

• Males or Females subjects aged 18-75 years.
• Subjects with chronic liver disease (cirrhosis)
• Pulmonary or extra-pulmonary tuberculosis.
• Serum ALT≤5times upper limit and serum bilirubin ≤3 mg/dl.
• consent and willingness to follow-up

Exclusion Criteria:

• Serum ALT>5times upper limit and serum bilirubin >3 mg/dl.
• Renal failure (serum creatinine>2mg/dl).
• Presence of hepatocellular carcinoma
• Alcoholic cirrhotic who continue to drink alcohol.
• Prior history of ATT (ANTI TUBERCULAR TREATMENT) with documented hepatotoxicity.
• Known hypersensitivity to levofloxacin, other quinolones